Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIV-509 in Adults With Moderate to Severe Atopic Dermatitis
NCT07167758Phase 2Active, not recruiting
- Sponsor
- Triveni Bio
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of TRIV-509 in atopic dermatitis (AD), sponsored by Triveni Bio. Started Aug 2025; status: active, not recruiting.
02
Drugs
TRIV-509
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07167758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07167758.